Literature DB >> 15946304

Neutropenic enterocolitis in adults: systematic analysis of evidence quality.

Marcus Gorschlüter1, Ulrich Mey, John Strehl, Carsten Ziske, Michael Schepke, Ingo G H Schmidt-Wolf, Tilman Sauerbruch, Axel Glasmacher.   

Abstract

OBJECTIVE: Neutropenic enterocolitis is a life-threatening complication occurring most frequently after intensive chemotherapy in acute leukaemias. The literature is heterogeneous and a systematic review is lacking.
METHODS: Following a systematic search we categorised all relevant reports according to their quality and extracted evidence to answer the questions: Which diagnostic criteria are appropriate? What is the incidence of neutropenic enterocolitis? Are there good quality studies supporting specific interventions: Which empiric antimicrobial therapy is recommendable? Is neutropenic enterocolitis without surgical emergency complications an indication for bowel resection?
RESULTS: We found and analysed 145 articles of these reports: 64 were reports of single cases, 30 papers reported of two or three cases, 13 were narrative reviews, 34 were retrospective case series of more than three cases and four were prospective diagnostic studies. There were no prospective trials or case control studies on the therapy of neutropenic enterocolitis. There was no consensus on diagnostic criteria. We discuss the difficulty to define diagnostic criteria without having a disease definition. Histology is mostly not available in the living patients. We suggest applying a combination of clinical and radiological criteria: fever, abdominal pain and any bowel wall thickening >4 mm detected by ultrasonography (US) or computed tomography. We calculated a pooled incidence rate from 21 studies of 5.3% (266/5058; 95% CI: 4.7%-5.9%) in patients hospitalised for haematological malignancies, for high-dose chemotherapy in solid tumours or for aplastic anaemia.
CONCLUSIONS: This systematic review provides diagnostic criteria for neutropenic enterocolitis, presents a quantitative synthesis on its incidence and discusses its treatment recommendations. Prospective studies are clearly warranted. (c) Blackwell Munksgaard 2005.

Entities:  

Mesh:

Year:  2005        PMID: 15946304     DOI: 10.1111/j.1600-0609.2005.00442.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  47 in total

1.  Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.

Authors:  Jennifer Dotson; Adee Elhamdani; Ellen Petryna; Muhammad Omer Jamil; Mohamed Alsharedi
Journal:  Int J Hematol       Date:  2018-12-03       Impact factor: 2.490

Review 2.  Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned.

Authors:  CelesteAnn T Bremer; Brian P Monahan
Journal:  Curr Gastroenterol Rep       Date:  2006-08

3.  Sonographic signs of neutropenic enterocolitis.

Authors:  Christoph-F Dietrich; Stella Hermann; Stefan Klein; Barbara Braden
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

4.  Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Authors:  Talha Badar; Damian R Handisides; Juliana M Benito; Mary Ann Richie; Gautam Borthakur; Elias Jabbour; Karine Harutyunyan; Sergej Konoplev; Stefan Faderl; Stew Kroll; Michael Andreeff; Tillman Pearce; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Marina Konopleva
Journal:  Am J Hematol       Date:  2016-06-25       Impact factor: 10.047

5.  Capecitabine-induced, nonneutropenic enterocolitis.

Authors:  Vallerie L Gordon; Gary A Harding; Piotr Czaykowski
Journal:  J Gastrointest Cancer       Date:  2011-12

Review 6.  Noninfectious colitides.

Authors:  Mohammed Bayasi; Jose Quiogue
Journal:  Clin Colon Rectal Surg       Date:  2015-06

7.  Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.

Authors:  Wendy M Kersemaekers; Peter Dogterom; Jialin Xu; Eugene E Marcantonio; Rik de Greef; Hetty Waskin; Marlou L P S van Iersel
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

8.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  Marina Konopleva; Peter F Thall; Cecilia Arana Yi; Gautam Borthakur; Andrew Coveler; Carlos Bueso-Ramos; Juliana Benito; Sergej Konoplev; Yongchuan Gu; Farhad Ravandi; Elias Jabbour; Stefan Faderl; Deborah Thomas; Jorge Cortes; Tapan Kadia; Steven Kornblau; Naval Daver; Naveen Pemmaraju; Hoang Q Nguyen; Jennie Feliu; Hongbo Lu; Caimiao Wei; William R Wilson; Teresa J Melink; John C Gutheil; Michael Andreeff; Elihu H Estey; Hagop Kantarjian
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

9.  Diagnosis and outcome of neutropenic enterocolitis: experience in a single tertiary pediatric surgical center in China.

Authors:  Kai Li; Shan Zheng; Kuiran Dong; Yijin Gao; Hongsheng Wang; Gongbao Liu; Jiechun Gao; Xianmin Xiao
Journal:  Pediatr Surg Int       Date:  2011-06-11       Impact factor: 1.827

10.  Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection.

Authors:  Ji Hun Kim; Jeong Won Jang; Chan Ran You; Si Young You; Mun Kyung Jung; Jin Hwan Jung
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.